Abstracts tagged "Minority Health"

Abstract Number: 1082 • ACR Convergence 2025
Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients
Rashi Vora¹, Samiha Karim², Dulaney Wilson³, Jasvinder Singh⁴, Gary Gilkeson¹, Jim Oates¹ and Diane Kamen⁵, ¹Medical University of South Carolina, Charleston, SC, ²Emory University, Atlanta, GA, ³Medical University of South Carolina, Charleston, ⁴Baylor College of Medicine, Houston, TX, ⁵Medical University of South Carolina, Johns Island, SC
Background/Purpose: Minority patients with systemic lupus erythematosus (SLE) experience a higher disease burden and encounter more barriers to care than White patients, resulting in worse…
Abstract Number: 1060 • ACR Convergence 2025
Demographic Risk Factors, Social Vulnerability Index, and Mortality in Patients with Systemic Lupus Erythematosus
Christine Kim¹, Katherine Mitchell², Changyong Feng¹ and Allen Anandarajah³, ¹University of Rochester, Rochester, NY, ²University of Rochester, Rochester, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement that is characterized by relapses and remissions. Ethnicity, socioeconomic status, gender, age, education…
Abstract Number: 2559 • ACR Convergence 2025
Increasing Clinical Trial Awareness in Sample of Underrepresented Systemic Lupus Erythematosus Patients
Leslie Ranken¹, Kyle Osborne², Robert Fairman³, Gregory Russell⁴, Sara Ohl² and Jessica Kearney-Bryan⁵, ¹Atrium Health Carolinas Medical Center Wake Forest School of Medicine Charlotte, Charlotte, NC, ²Atrium Health, Charlotte, NC, ³Wellstar Health, Marietta, GA, ⁴Wake Forest School of Medicine, Winston-Salem, NC, ⁵Atrium Health Carolinas Medical Center, Charlotte, NC
Background/Purpose: Underrepresented Systemic Lupus Erythematosus (SLE) patients are greatly underrepresented in SLE clinical trials. We aimed to increase clinical trial awareness with various interventions in…
Abstract Number: 2199 • ACR Convergence 2025
Disparities in Reproductive Health Counseling Among Hispanic Women with Autoimmune Rheumatic Diseases: Insights from a Patient-Reported Survey in an Urban Safety-Net Setting
Eaman Alhassan¹, Laura Kobashigawa², Vanessa Ramos², Jack Rodman² and Leanna Wise³, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Southern California, Los Angeles, ³LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: Reproductive-age Hispanic women with rheumatoid arthritis, juvenile idiopathic arthritis (combined, inflammatory arthritis; IA), and systemic lupus erythematosus (SLE) often bear a higher disease burden…
Abstract Number: 2198 • ACR Convergence 2025
Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
Andrew Ramirez¹, Alexa Montes de Oca¹, Martha Delgado¹, Mellissa withers¹ and Leanna Wise², ¹University of Southern California, Los Angeles, ²LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: As systemic lupus erythematosus (SLE) often affects women of child-bearing age, understanding how this population makes reproductive health decisions is critical for well-rounded healthcare.…
Abstract Number: 2077 • ACR Convergence 2025
Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans
Tam Dinh¹, Evelyn Inga¹, Janelle Francisco¹, Yvonne Waters¹, Krystle Tapia², Maheswari Muruganandam³, N. Suzanne Emil¹, Frank O'Sullivan¹ and Wilmer Sibbitt³, ¹University of New Mexico, Albuquerque, ²University of New Mexico Hospital, Albuquerque, NM, ³University of New Mexico, Albuquerque, NM
Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is an aggressive subtype of idiopathic inflammatory myopathy (IIM) associated anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) antibodies. Recently there have been…
Abstract Number: 2074 • ACR Convergence 2025
Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients
Sergio Maldonado Chaar¹ and Kelly Corbitt², ¹University of Miami/Jackson Health, Miami, FL, ²University of Miami Miller School of Medicine, El Portal, FL
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA-5) antibody positivity in dermatomyositis (DM) is often associated with development of interstitial lung disease (ILD), with factors such as…
Abstract Number: 1915 • ACR Convergence 2025
Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence
Brandon Jackson¹, Roberto Caricchio², Saira Sheikh³, Meenakshi Jolly⁴, Jennifer Meriwether⁵, Taylor Irons⁶, Taylor Adjei⁷, Caroline Donovan⁸, Carla Menezes⁷, Courtney Canton⁹, Aimee Williams¹⁰, Maya Merrell⁹ and Stacie Bell¹¹, ¹Lupus Therapeutics, Miami, FL, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Rush University, Chicago, IL, ⁵Lupus Therapeutics, Westminster, CO, ⁶Lupus Therapeutics, Houston, TX, ⁷Lupus Therapeutics, New York, NY, ⁸Lupus Therapeutics, Charlottesville, VA, ⁹Lupus Therapeutics, Charleston, SC, ¹⁰Lupus Therapeutics, Raleigh, NC, ¹¹Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus disproportionately impacts racial and ethnic minorities, yet these groups remain underrepresented in clinical trials. Lupus Therapeutics, overseeing the Lupus Clinical Investigators Network (LuCIN),…
Abstract Number: 1232 • ACR Convergence 2025
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Jerik Leung¹, Tomika Caldwell², Paul Nietert³, Clara Dismuke⁴, Hetlena Johnson⁵, Edith Williams⁶ and Everette Keller³, ¹Emory University, Rollins School of Public Health, Atlanta, GA, ²Medical University of Souty Carolina, Charleston, ³Medical University of South Carolina, Charleston, SC, ⁴VA Palo Alto Health Care System, Menlo Park, ⁵Lupus Community Advocate/Researcher, Columbia, SC, ⁶University of Rochester Medical Center, Rochester, NY
Background/Purpose: Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health related bodily…
Abstract Number: 1023 • ACR Convergence 2024
Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors
Igor Dombrovsky¹, Michael George², Joshua Baker² and Thomas Riley³, ¹Pennsylvania Hospital, Philadephia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Hopsital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Access to Janus kinase inhibitors (JAKi) is controlled by insurance carriers through prior authorizations and the use of restricted formularies. We previously showed that…
Abstract Number: 1230 • ACR Convergence 2024
Mediating Role of Pain Catastrophizing in Racial Disparities in Knee Osteoarthritis Pain Among Non-Hispanic White and Asian Americans: A Pilot Study
Chiyoung Lee¹, Kent Kwoh² and Hyochol Ahn¹, ¹University of Arizona College of Nursing, Tucson, AZ, ²University of Arizona, Tucson, AZ
Background/Purpose: The prevalence of symptomatic knee osteoarthritis (OA) is projected to increase among racially and ethnically marginalized groups. Although recent studies have begun to delineate…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…
Abstract Number: 1761 • ACR Convergence 2024
Juvenile Idiopathic Arthritis Genetic Risk Haplotypes: Relevance to Children of African Ancestry
Sabrina George¹, Hannah C Ainsworth², Kaiyu Jiang³, Gilad Barshad⁴, Adam He⁴, Edward Rice⁴, Carl D Langerfeld², Charles G Danko⁴ and James N Jarvis³, ¹University at Buffalo Jacobs School of Medicine, Buffalo, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Cornell University Baker School of Veterinary Medicine, Ithaca, NY
Background/Purpose: - Numerous juvenile idiopathic arthritis (JIA) risk loci have been identified, overwhelmingly from cohorts of children of European ancestry (EA). The extent to which…
Abstract Number: 1917 • ACR Convergence 2024
Access to Rheumatology Care near Indian Health Service Hospitals for American Indian Communities
Tristan Furnary¹, Rachel Wallwork², Megan Lockwood³, Brooke Montgomery⁴, Caleb Bolden⁴, Siobhan Wescott⁵, Matthew Tobey⁴ and Marcy Bolster⁴, ¹Harvard Medical School, Brookline, MA, ²Johns Hopkins University, Towson, MD, ³Medstar Georgetown University Hospital, Washington, DC, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Geographic barriers to subspecialty care among American Indian (AI) populations are poorly defined. Mapping the geographic distribution of rheumatology providers is a crucial step…
Abstract Number: 1939 • ACR Convergence 2024
Patient’s Satisfaction with a Telerheumatology Program in a Remote Rural Area of Northern Pakistan
Tayyeba Khursheed¹, Usman A. Raza², Uzma Rasheed¹ and Wajahat Aziz¹, ¹Pakistan Institute of Medical Sciences, Islamabad, Islamabad, Pakistan, ²ClaritasRx, South San Fransisco, CA
Background/Purpose: Telerheumatology has emerged as a promising tool for improving access to rheumatology services globally. Health delivery in remote rural areas is particularly challenging. Telerheumatology…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].